Smart inhaler powder with functional adaptation to drug formulation (Q78354): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Label in wikidata changed) |
(Created claim: summary (P836): SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014)an inhaler dried powder (DPI), which, in the context of competition within this segment of the market for inhalation, will be distinguished in two fundamental aspects — the design and function.In...) |
||
| Property / summary | |||
SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014)an inhaler dried powder (DPI), which, in the context of competition within this segment of the market for inhalation, will be distinguished in two fundamental aspects — the design and function.In the design of the inhaler, the applicant will use an innovative approach to build it with interchangeable components.Their modification as a result of the R & D work will allow the inhaler to be adjusted quickly and cheaply to any given formula of the inhalation drug in a capsule.From the point of view of functionality, the Plinino inhalator will have a number of technological solutions which lend itself to the nature of the & bthumb system; a smart & core; not having any equivalent available on the market as well as from the developed fireplaces of the DPI.These functionalities will include, inter alia, the verification of the position of an inhaler during the medicine’s application;measurement of the timing and intensity of the administration of the medicine;perforation function of the capsules;the possibility to locate the medicine’s place of life.Convinced of the interest in the treatment of pharmaceutical companies (& bdquo; generic & core; but also & bdnquo; original & core;) which is the target group of purchasers of the project’s results, is justified in several respects.Companies that already possess inhalation medicines in the form of capsules, choosing to change their inhaler to the more advanced DPI, will be able to remain in the current formulation.Conversely, companies that were not previously in the portfolio of inhalation medicines could fit the inhalator Pulin to one developed composition of the medicine, instead of developing a number of further iterations of the formula tailored to the structure of the inhaler.The project will lead to the development of a complete device. (English) | |||
| Property / summary: SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014)an inhaler dried powder (DPI), which, in the context of competition within this segment of the market for inhalation, will be distinguished in two fundamental aspects — the design and function.In the design of the inhaler, the applicant will use an innovative approach to build it with interchangeable components.Their modification as a result of the R & D work will allow the inhaler to be adjusted quickly and cheaply to any given formula of the inhalation drug in a capsule.From the point of view of functionality, the Plinino inhalator will have a number of technological solutions which lend itself to the nature of the & bthumb system; a smart & core; not having any equivalent available on the market as well as from the developed fireplaces of the DPI.These functionalities will include, inter alia, the verification of the position of an inhaler during the medicine’s application;measurement of the timing and intensity of the administration of the medicine;perforation function of the capsules;the possibility to locate the medicine’s place of life.Convinced of the interest in the treatment of pharmaceutical companies (& bdquo; generic & core; but also & bdnquo; original & core;) which is the target group of purchasers of the project’s results, is justified in several respects.Companies that already possess inhalation medicines in the form of capsules, choosing to change their inhaler to the more advanced DPI, will be able to remain in the current formulation.Conversely, companies that were not previously in the portfolio of inhalation medicines could fit the inhalator Pulin to one developed composition of the medicine, instead of developing a number of further iterations of the formula tailored to the structure of the inhaler.The project will lead to the development of a complete device. (English) / rank | |||
Normal rank | |||
Revision as of 09:12, 4 March 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Smart inhaler powder with functional adaptation to drug formulation |
Project in Poland financed by DG Regio |
Statements
5,109,751.41 zloty
0 references
6,923,416.09 zloty
0 references
73.8 percent
0 references
1 November 2017
0 references
31 December 2019
0 references
PULINNO SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
0 references
53°7'46.9"N, 18°1'45.8"E
0 references
SA.41471(2015/X) Przeznaczenie_pomocy_publicznej: art. 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26.06.2014)Projekt dotyczy opracowania inteligentnego „kapsułkowego” inhalatora suchego proszku (DPI), który na tle konkurencji w tym segmencie rynku wyrobów do inhalacji będzie wyróżniał się w dwóch podstawowych aspektach - konstrukcyjnym i funkcjonalnym. W konstrukcji inhalatora Wnioskodawca zastosuje nowatorskie podejście nadając mu modułową budowę z wymiennymi elementami. Ich modyfikacja w wyniku przeprowadzonych prac B+R pozwoli na szybkie i tanie dopasowanie inhalatora do każdej zadanej formulacji leku wziewnego w kapsułce. Z punktu widzenia funkcjonalności inhalator Pulinno będzie posiadał szereg rozwiązań technologicznych, nadających mu charakter urządzenia „inteligentnego”, nie mającego swojego odpowiednika w dostępnych na rynku, jak i rozwijanych kominkowych DPI. Do funkcjonalności tych należeć będą, m.in. weryfikacja pozycji inhalatora w czasie aplikacji leku; pomiar czasu i intensywności podawania leku; funkcja pomiaru przebicia kapsułki; czy możliwość lokalizacji miejsca zażycia leku. Przekonanie o zainteresowaniu tym rozwiązaniem firm farmaceutycznych („generycznych”, ale również „oryginalnych”), stanowiących docelową grupę nabywców rezultatów projektu, znajduje uzasadnienie w kilku aspektach. Firmy już posiadające leki wziewne w postaci kapsułki, decydując się na zmianę swojego inhalatora na bardziej zaawansowany DPI Pulinno będą mogły pozostać przy obecnej formulacji. Z kolei firmy, które nie miały wcześniej w portfelu leków wziewnych będą mogły dopasować inhalator Pulinno do jednej opracowanej kompozycji leku, zamiast rozwijać szereg kolejnych iteracji formulacji dopasowywanych do konstrukcji inhalatora. W projekcie dojdzie do opracowania kompletnego urządzenia. (Polish)
0 references
SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014)an inhaler dried powder (DPI), which, in the context of competition within this segment of the market for inhalation, will be distinguished in two fundamental aspects — the design and function.In the design of the inhaler, the applicant will use an innovative approach to build it with interchangeable components.Their modification as a result of the R & D work will allow the inhaler to be adjusted quickly and cheaply to any given formula of the inhalation drug in a capsule.From the point of view of functionality, the Plinino inhalator will have a number of technological solutions which lend itself to the nature of the & bthumb system; a smart & core; not having any equivalent available on the market as well as from the developed fireplaces of the DPI.These functionalities will include, inter alia, the verification of the position of an inhaler during the medicine’s application;measurement of the timing and intensity of the administration of the medicine;perforation function of the capsules;the possibility to locate the medicine’s place of life.Convinced of the interest in the treatment of pharmaceutical companies (& bdquo; generic & core; but also & bdnquo; original & core;) which is the target group of purchasers of the project’s results, is justified in several respects.Companies that already possess inhalation medicines in the form of capsules, choosing to change their inhaler to the more advanced DPI, will be able to remain in the current formulation.Conversely, companies that were not previously in the portfolio of inhalation medicines could fit the inhalator Pulin to one developed composition of the medicine, instead of developing a number of further iterations of the formula tailored to the structure of the inhaler.The project will lead to the development of a complete device. (English)
0 references
Identifiers
POIR.01.01.01-00-0810/17
0 references